Conjunctivitis Treatment Market Report 2026

The conjunctivitis treatment market size has grown steadily in recent years. It will grow from $4.89 billion in 2025 to $5.1 billion in 2026 at a compound annual growth rate (CAGR) of 4.3%. The growth in the historic period can be attributed to high incidence of eye infections, widespread bacterial and viral exposure, limited access to ophthalmology care, reliance on topical antibiotics, seasonal allergy prevalence.

The conjunctivitis treatment market size is expected to see steady growth in the next few years. It will grow to $6.13 billion in 2030 at a compound annual growth rate (CAGR) of 4.7%. The growth in the forecast period can be attributed to increasing awareness of eye hygiene, rising self-medication trends, growth of otc ophthalmic products, expanding urban populations, improved access to eye care. Major trends in the forecast period include rising demand for preservative-free eye drops, increased use of combination drug formulations, growth in over-the-counter treatment adoption, focus on faster symptom relief therapies, expansion of homecare-based treatment.

The growing geriatric population is expected to support the expansion of the conjunctivitis treatment market. The geriatric population consists of elderly individuals within a population. Older adults are more vulnerable to various eye-related conditions, including conjunctivitis, due to factors such as weakened immune function, existing medical conditions, and age-related changes in eye health that increase susceptibility to infections. For example, in July 2024, according to the UK Parliament’s House of Commons Library, a UK-based government administration, there were 12.7 million people aged 65 years or older in the UK in 2022, accounting for 19% of the total population. This figure is projected to rise to 22.1 million by 2072, representing 27% of the population. Consequently, the expanding geriatric population is contributing to the growth of the conjunctivitis treatment market.

Companies operating in the conjunctivitis treatment market are increasingly emphasizing product development and new launches, including ophthalmic products, to maintain their competitive position. Ophthalmic products are medical and pharmaceutical solutions specifically designed for eye care and the treatment of vision-related conditions. For instance, in July 2023, Harrow, Inc., a US-based ophthalmic healthcare company specializing in pharmaceutical products for eye surgeries and conditions such as dry eye disease, glaucoma, allergies, and infections, introduced five new ophthalmic products in the United States. FLAREX (fluorometholone acetate ophthalmic suspension) 0.1% is intended for steroid-responsive inflammatory eye conditions, while NATACYN (natamycin ophthalmic suspension) 5% remains the only FDA-approved topical ophthalmic antifungal for treating fungal blepharitis, conjunctivitis, and keratitis. TOBRADEX ST (tobramycin/dexamethasone ophthalmic suspension) 0.3%/0.05% is formulated for inflammatory ocular conditions where corticosteroid use is required alongside a risk of bacterial infection. VERKAZIA (cyclosporine ophthalmic emulsion) 0.1%, a patented orphan-designated product, is used to treat vernal keratoconjunctivitis in both pediatric and adult patients. Finally, ZERVIATE (cetirizine ophthalmic solution) 0.24% is indicated for the relief of ocular itching associated with allergic conjunctivitis. This broad product launch highlights Harrow, Inc.’s focus on delivering diverse and targeted ophthalmic treatment options.

In July 2023, Harrow Health Inc., a US-based healthcare company, acquired the branded ophthalmic portfolio of Santen Pharmaceutical Co., Ltd. for an undisclosed amount. Through this acquisition, Harrow Health sought to strengthen its presence in the North American market by expanding its ophthalmic product offerings and commercial reach, thereby enhancing product diversity and revenue opportunities across the United States and Canada. Santen Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company specializing in the research, development, and commercialization of ophthalmic therapies and products.

Major companies operating in the conjunctivitis treatment market are Alcon Laboratories Inc., Santen Pharmaceuticals Co. Ltd, Eyevance Pharmaceuticals LLC, Johnson and Johnson, Bausch Health Companies Inc., Cipla Inc., Dr Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Lupin Limited, Alembic Pharmaceuticals Ltd., Akorn Inc., Micro Labs Ltd., Ocular Therapeutics Inc., GlaxoSmithKline plc, Merck & Co Inc, Vanda Pharmaceuticals, Aldeyra Therapeutics, Allakos Inc, Regeneron Pharmaceuticals, Marinomed Biotech AG, Eleusis Holdings Ltd, IACTA Pharmaceuticals, Nanomerics, OKYO Pharma, Stuart Therapeutics.

North America was the largest region in the conjunctivitis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the conjunctivitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the conjunctivitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the conjunctivitis treatment market by increasing costs of imported ophthalmic drugs, active pharmaceutical ingredients, packaging materials, and manufacturing inputs. Hospitals and specialty eye clinics in North America and Europe are most affected due to reliance on imported formulations, while Asia-Pacific experiences higher costs for raw materials. These tariffs are increasing product prices. However, they are also encouraging local drug production, generic formulation development, and improved regional supply resilience.

The conjunctivitis treatment market research report is one of a series of new reports that provides conjunctivitis treatment market statistics, including conjunctivitis treatment industry global market size, regional shares, competitors with a conjunctivitis treatment market share, detailed conjunctivitis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the conjunctivitis treatment industry. This conjunctivitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Conjunctivitis treatment refers to the medical care and therapeutic approaches used to manage and resolve the symptoms and root causes of conjunctivitis, commonly known as pink eye. It involves the use of different medications to control inflammation, ease discomfort, and prevent the transmission of infection.

The primary drug types used for conjunctivitis treatment include antibiotics, antivirals, anti-allergic agents, and artificial tears. Antibiotics are medications used to treat bacterial infections by either eliminating bacteria or restricting their growth and are frequently prescribed for conjunctivitis caused by bacterial organisms to reduce inflammation and clear the infection. These drugs are used in the treatment of conditions such as allergic conjunctivitis, bacterial conjunctivitis, and viral conjunctivitis and are administered through oral and topical routes. They are utilized by end users including hospitals, home care settings, specialty clinics, and others.

The conjunctivitis treatment market consists of revenues earned by entities by providing antibiotic therapy and eye-warming therapy services. The market value includes the value of related goods sold by the service provider or included within the service offering. The conjunctivitis treatment market also includes sales of eye drops, ointments, ophthalmic steroids, non-steroidal anti-inflammatory drugs, and antihistamines, which are used in conjunctivitis treatment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.